Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 34.5% during trading on Thursday . The company traded as high as C$0.24 and last traded at C$0.20. 825,700 shares changed hands during mid-day trading, an increase of 75% from the average session volume of 472,417 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The firm has a 50-day moving average price of C$0.09 and a two-hundred day moving average price of C$0.07. The company has a market capitalization of C$16.99 million, a price-to-earnings ratio of -9.75 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Most active stocks: Dollar volume vs share volume
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Bank Stocks – Best Bank Stocks to Invest In
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Ride Out The Recession With These Dividend Kings
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
